In non‐small cell lung cancer (NSCLC) patients resistant to first‐ or second‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), only half develop the T790M mutation and thus qualify for the treatment using third‐generation EGFR‐TKIs. The gene discussed is EGFR; the disease is lung cancer.